Published in Methods Enzymol on January 01, 2012
Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med (2014) 1.23
Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A (2014) 0.98
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner. Atherosclerosis (2013) 0.94
Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. ACS Nano (2015) 0.90
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
Attenuation correction for flexible magnetic resonance coils in combined magnetic resonance/positron emission tomography imaging. Invest Radiol (2014) 0.84
Atherosclerotic plaque inflammation quantification using dynamic contrast-enhanced (DCE) MRI. Quant Imaging Med Surg (2013) 0.82
Three-dimensional dynamic contrast-enhanced MRI for the accurate, extensive quantification of microvascular permeability in atherosclerotic plaques. NMR Biomed (2015) 0.79
Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine (2015) 0.79
Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Curr Cardiovasc Imaging Rep (2012) 0.79
Detection of vulnerable atherosclerotic plaque and prediction of thrombosis events in a rabbit model using 18F-FDG -PET/CT. PLoS One (2013) 0.78
Registration of dynamic contrast-enhanced MRI of the common carotid artery using a fixed-frame template-based squared-difference method. J Magn Reson Imaging (2013) 0.76
The melding of nanomedicine in thrombosis imaging and treatment: a review. Future Sci OA (2016) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2010) 5.26
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation (2002) 4.43
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med (2006) 3.63
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2003) 2.77
Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging (2002) 2.55
Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging (2005) 2.54
Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging (2010) 2.38
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation (2003) 2.15
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology (2006) 1.80
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med (2008) 1.57
Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging (2006) 1.45
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med (2006) 1.27
Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov (2008) 1.26
Developments in liposomal drug delivery systems. Expert Opin Biol Ther (2001) 1.25
Diffusion and perfusion of the kidney. Eur J Radiol (2010) 1.16
Technical aspects of MR perfusion. Eur J Radiol (2010) 1.12
Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. Radiology (2011) 1.08
Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis (2010) 1.05
Reproducibility of black blood dynamic contrast-enhanced magnetic resonance imaging in aortic plaques of atherosclerotic rabbits. J Magn Reson Imaging (2010) 0.97
Hypercholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery. Circulation (1991) 0.95
A general dual-bolus approach for quantitative DCE-MRI. Magn Reson Imaging (2010) 0.95
Noise and motion correction in dynamic contrast-enhanced MRI for analysis of atherosclerotic lesions. Magn Reson Med (2002) 0.94
Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv (2005) 0.92
Standardization of models and methods used to assess nanoparticles in cardiovascular applications. Small (2011) 0.88
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol (2006) 3.36
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Endosomal escape pathways for delivery of biologicals. J Control Release (2010) 2.90
In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation (2005) 2.69
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med (2007) 2.26
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 2.09
Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med (2006) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
Optimization of ex vivo CT- and MR- imaging of atherosclerotic vessel wall changes. Int J Cardiovasc Imaging (2004) 2.04
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
Cytoarchitecture of the human cerebral cortex: MR microscopy of excised specimens at 9.4 Tesla. AJNR Am J Neuroradiol (2002) 1.98
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes (2006) 1.97
MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med (2012) 1.92
Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology (2009) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging (2012) 1.85
Theranostic nanomedicine. Acc Chem Res (2011) 1.84
Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res (2010) 1.83
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol (2002) 1.79
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood (2003) 1.74
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes (2006) 1.74
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol (2005) 1.73
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab (2008) 1.71
Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov (2004) 1.71
Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol (2002) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol (2005) 1.67
Mouse model of heterotopic aortic arch transplantation. J Surg Res (2003) 1.66
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release (2003) 1.63
Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release (2010) 1.63
Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett (2008) 1.62
Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm (2010) 1.60
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol (2004) 1.58
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Risk scores predict atherosclerotic lesions in young people. Arch Intern Med (2005) 1.56
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Assessment of myocardial perfusion and viability from routine contrast-enhanced 16-detector-row computed tomography of the heart: preliminary results. Eur Radiol (2005) 1.55
IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J Immunol (2006) 1.54
The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol (2005) 1.53
Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging (2007) 1.52
In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging (2008) 1.52
A review of CETP and its relation to atherosclerosis. J Lipid Res (2004) 1.50
CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol (2004) 1.50
Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol (2011) 1.50
Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. JACC Cardiovasc Imaging (2012) 1.48
Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Control Release (2012) 1.48
Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm (2013) 1.48
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc Imaging (2012) 1.46
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46